Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

PHASE4TerminatedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2018

Study Completion Date

August 31, 2018

Conditions
Diabetic RetinopathyHIV
Interventions
DRUG

Tesamorelin

Daily 2 mg subcutaneous injections of tesamorelin

DRUG

Placebo-Control

3.0 mL vials

Trial Locations (24)

20036

Capital Medical Associates, PC, Washington D.C.

32809

Orange County Health Department, Orlando

33305

Rowan Tree Medical , P.A., Wilton Manors

33316

Gary J. Richmond, M.D., PA, Fort Lauderdale

33401

Triple O Research Institute, West Palm Beach

63108

Southampton Clinical Research, Inc d.b.a. Central West Clinical Research, St Louis

63139

Southampton Healthcare, Inc., St Louis

73104

Harold Hamm Diabetes Center at the University of Oklahoma, Oklahoma City

75216

Dallas VA Medical Center, Dallas

75235

UT Southwestern Medical Center, Atten: HIV Research Unit, Dallas

77098

Research Access Network, Houston

77401

St. Hope Foundation, Inc., Bellaire

78705

Central Texas Clinical Research, Austin

85004

Southwest Center for HIV/AIDS, Phoenix

85012

Spectrum Medical Group, Phoenix

90033

5P21 Rand Schrader Clinic, Los Angeles

90035

University of California CARE Clinic, Los Angeles, Los Angeles

92103

UCSD Antiviral Research Center, San Diego

92262

Palmtree Clinical Research, Inc., Palm Springs

94121

VAMC, Infectious Disease Section 111W, San Francisco

97219

Fanno Creek Clinic, LLC, Portland

98112

Virginia Mason Medical Center, Seattle

48072-3436

Be Well Medical Center, P.C., Berkley

08244

South Jersey Infectious Disease, Somers Point

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theratechnologies

INDUSTRY